Pyxis secured S$13 million in the first close of its S$18 million growth funding round, reflecting strong investor confidence in its vessel technology, commercial traction, and regional growth ...

Fintel reports that on December 19, 2025, HC Wainwright & Co. maintained coverage of Pyxis Oncology (NasdaqGS:PYXS) with a Buy recommendation. Analyst Price Forecast Suggests 474.27% Upside As of ...

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an ...

Pyxis Tankers Inc. operates as a maritime transportation company with a focus on the tanker and dry-bulk sectors in the United States and internationally. It operates through two segments: Tanker ...

RBC Capital analyst Leonid Timashev lowered the firm’s price target on Pyxis Oncology (PYXS) to $5 from $8 and keeps an Outperform rating on the shares. The company reported phase 1 data from their ...

A first look at Canon-powered Vaonis Hyperia – a smart telescope that brings professional observatory-level astrophotography ...

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Ronald Taylor is a director of Actavis and Red Lion Hotels Corp. In 1987, Mr Taylor founded Pyxis Corporation where he served as chair, president and chief executive officer until its purchase by ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. Chart does not reflect ...

See Pyxis Tankers Inc. (PXS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.